Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
- PMID: 17895355
- DOI: 10.1136/gut.2007.128611
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
Abstract
Background and aims: The gold standard treatment of chronic hepatitis C (CHC) is combined pegylated interferon and ribavirin. Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC.
Methods: Group A (training set) comprised 40 patients with CHC including 14 non-responders (NRs) and 26 sustained virological responders (SVRs). Group B (validation set) comprised 29 patients including 9 NRs and 20 SVRs. Eleven responder-relapsers were also included. A total of 58 genes associated with liver gene expression dysregulation during CHC were selected from the literature. Real-time quantitative RT-PCR assays were used to analyse the mRNA expression of these 58 selected genes in liver biopsy specimens taken from the patients before treatment.
Results: From the Group A data, three genes whose expression was significantly increased in NRs compared with SVRs were identified: IFI-6-16/G1P3, IFI27 and ISG15/G1P2. These three genes also showed significant differences in their expression profiles between NRs and SVRs in the independent sample (Group B). Supervised class prediction analysis identified a two-gene (IFI27 and CXCL9) signature, which accurately predicted treatment response in 79.3% (23/29) of patients from the validation set (Group B), with a predictive accuracy of 100% (9/9) and of 70% (14/20) in NRs and SVRs, respectively. The expression profiles of responder-relapsers did not differ significantly from those of NRs and SVRs, and 73% (8/11) of them were predicted as SVRs with the two-gene classifier.
Conclusion: NRs and SVRs have different liver gene expression profiles before treatment. The most notable changes occurred mainly in interferon-stimulated genes. Treatment response could be predicted with a two-gene signature (IFI27 and CXCL9).
Similar articles
-
IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.PLoS One. 2015 Apr 6;10(4):e0121395. doi: 10.1371/journal.pone.0121395. eCollection 2015. PLoS One. 2015. PMID: 25844942 Free PMC article.
-
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.Gastroenterology. 2010 Mar;138(3):1123-33.e1-3. doi: 10.1053/j.gastro.2009.10.046. Epub 2009 Nov 6. Gastroenterology. 2010. PMID: 19900446
-
Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.World J Gastroenterol. 2015 Mar 21;21(11):3291-9. doi: 10.3748/wjg.v21.i11.3291. World J Gastroenterol. 2015. PMID: 25805936 Free PMC article.
-
Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.Liver Int. 2010 Apr;30(4):567-73. doi: 10.1111/j.1478-3231.2010.02212.x. Liver Int. 2010. PMID: 20456039
-
Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.Mediators Inflamm. 2015;2015:287640. doi: 10.1155/2015/287640. Epub 2015 Apr 19. Mediators Inflamm. 2015. PMID: 25969625 Free PMC article. Review.
Cited by
-
IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.PLoS One. 2015 Apr 6;10(4):e0121395. doi: 10.1371/journal.pone.0121395. eCollection 2015. PLoS One. 2015. PMID: 25844942 Free PMC article.
-
Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection.Liver Int. 2015 Oct;35(10):2256-64. doi: 10.1111/liv.12830. Epub 2015 Apr 7. Liver Int. 2015. PMID: 25800823 Free PMC article.
-
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.Genes Immun. 2014 Mar;15(2):88-94. doi: 10.1038/gene.2013.66. Epub 2014 Jan 16. Genes Immun. 2014. PMID: 24335707
-
Individualization of chronic hepatitis C treatment according to the host characteristics.World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839. World J Gastroenterol. 2014. PMID: 24659876 Free PMC article. Review.
-
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.World J Gastroenterol. 2013 Nov 28;19(44):7852-66. doi: 10.3748/wjg.v19.i44.7852. World J Gastroenterol. 2013. PMID: 24307779 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous